Memantine hydrochloride for prevention of cognitive decline and disease progression in older people with Down's syndrome

Phase 4, randomised, double-blind trial in No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity, Dementia and Down syndrome comparing Memantine hydrochloride with Placebo (2 arms). Primary endpoints: Primary: Efficacy of memantine vs placebo on cognitive decline and disease progression and Primary: Safety of memantine hydrochloride. Started Jul 2005; status: completed.